

CITATION REPORT

List of articles citing

Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report

DOI: 10.1016/j.chest.2018.07.040
Chest, 2018, 154, 1121-1201.

Source: <https://exaly.com/paper-pdf/71692470/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
631	Anticoagulation therapy in Australia. 2018 , 3, 48-48		7
630	2018 Korean Guideline of Atrial Fibrillation Management. 2018 , 48, 1033-1080		68
629	Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. 2018 , 118, 2171-2187		96
628	Integrated care for the management of atrial fibrillation: what are the key components and important outcomes?. 2019 , 21, 1759-1761		2
627	Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists. 2019 , 47, 113-122		11
626	An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. 2019 , 394, 861-867		360
625	Consensus Clinical Decision-Making Factors Driving Anticoagulation in Atrial Fibrillation. 2019 , 124, 1038-1043	2	
624	Direct-Acting Oral Anticoagulants in Critically Ill Patients. <i>Chest</i> , 2019 , 156, 604-618	5.3	4
623	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. 2019 , 76, 1192-1202		49
622	Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. 2019 , 296, 65-70		9
621	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). 2019 , 21, 1603-1604		33
620	Screening for atrial fibrillation: Need for an integrated, structured approach. 2019 , 67, 33-35		9
619	Clinical factors and imaging leading to risk of incident atrial fibrillation. 2019 , 20, 988-989		
618	Direct oral anticoagulants in patients with cancer. 2019 , 76, 1019-1027		1
617	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. 2019 , 73, 3295-3308		61
616	Intracranial Hemorrhage and Intracranial Hypertension. 2019 , 37, 529-544		14
615	Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. 2019 , 38, 1168-1184.e1		156

614	Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. 2019 , 119, 1695-1703	85
613	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. 2019 , 3, 431-497	5
612	Stroke risk is not static for certain patients with AF. 2019 , 25, 6	
611	The effect of heparin infusion intensity on outcomes for bridging hospitalized patients with atrial fibrillation. 2019 , 42, 995-1002	2
610	Use of simplified HAS-BLED score in patients with atrial fibrillation receiving warfarin. 2019 , 35, 711-715	1
609	Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. 2019 , 33, 824-836	31
608	Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range. 2019 , 74, 2431-2433	
607	Contraindication to Anticoagulation in Nonvalvular Atrial Fibrillation: Are We Still to Fear the Clot and Not the Bleed?. 2019 , 5, 1393-1395	2
606	Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. 2019 , 74, 2204-2215	45
605	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. 2019 , 42, 1147-1154	8
604	Association between epicardial adipose tissue and embolic stroke after catheter ablation of atrial fibrillation. 2019 , 30, 2209-2216	2
603	Atrial Fibrillation in Older People: Concepts and Controversies. 2019 , 6, 175	30
602	Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. 2019 , 13, 1363-1373	16
601	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting. 2019 , 76, 1395-1402	2
600	Associations between anticoagulant treatment pathways and self-reported harms in patients recently diagnosed with venous thromboembolism. 2019 , 182, 95-100	
599	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. 2019 , 119, 1901-1919	36
598	Antidotes for reversal of direct oral anticoagulants. 2019 , 204, 107405	6
597	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. 2019 , 74, 2365-2375	142

596	Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management. 2019 , 119, 1550-1552	0
595	Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants. 2019 , 55,	5
594	Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. 2019 , 42, 1409-1422	8
593	A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention. 2019 , 18, 1119-1125	2
592	First evidence for a pharmacist-led anticoagulant clinic in a medicare part A long term care environment. 2019 , 48, 690-693	1
591	DOACs are the preferred anticoagulants for many with nonvalvular AF. 2019 , 25, 6	
590	Nurse-led vs. usual-care for atrial fibrillation. 2020 , 41, 634-641	30
589	Spread the Word About CHEST in 2019: Innovations, Introductions, and Farewells. <i>Chest</i> , 2019 , 155, 1-4	53
588	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. 2019 , 119, 576-585	6
587	Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process. 2019 , 35, 611-618	20
586	Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. 2019 , 39, 758-769	43
585	Periprocedural Anticoagulation for Cardioversion of Acute Onset Atrial Fibrillation and Flutter: Evidence Base for Current Guidelines. 2019 , 35, 1301-1310	12
584	Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. 2019 , 50, 2245-2249	40
583	Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke. 2019 , 50, 2223-2226	9
582	Using Blood Biomarkers to Identify Atrial Fibrillation-Related Stroke. 2019 , 50, 1956-1957	1
581	Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. 2019 , 124, 879-885	16
580	Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey. 2019 , 180, 25-27	1
579	The Use of Rivaroxaban in Patients With Atrial Fibrillation Receiving Hemodialysis-Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2019 , 155, 1306-1307	53 1

578	Response. <i>Chest</i> , 2019 , 155, 1307	5-3	
577	Prothrombin Complex Concentrate or Coagulation Factor Xa (Recombinant), Inactivated-zhzo. <i>Chest</i> , 2019 , 155, 1308	5-3	2
576	Value and Timing of Repeat Spirometry or Feno in Children: With Asthma Remains Unclear. <i>Chest</i> , 2019 , 155, 1312-1313	5-3	
575	The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban. <i>Chest</i> , 2019 , 155, 1309-1311	5-3	
574	Response. <i>Chest</i> , 2019 , 155, 1309	5-3	0
573	Response. <i>Chest</i> , 2019 , 155, 1311-1312	5-3	
572	Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. 2019 , 180, 10-19		31
571	Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Chest</i> , 2019 , 156, 529-543	5-3	62
570	Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. 2019 , 67, 1662-1671		25
569	Oral anticoagulant monitoring: Are we on the right track?. 2019 , 41 Suppl 1, 40-48		4
568	Atrial Fibrillation and End-Stage COPD: A Close Association Revisited. <i>Chest</i> , 2019 , 155, 888-889	5-3	1
567	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. 2019 , 50, 1372-1379		29
566	Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. 2019 , 58, 1265-1279		75
565	Risk of atrial fibrillation in patients with nonalcoholic steatohepatitis. 2019 , 39, 818-820		
564	Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. 2019 , 50, 1480-1489		8
563	Stroke risk stratification in atrial fibrillation: a review of common risk factors. 2019 , 9, 113-120		18
562	Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies. 2019 , 8,		25
561	Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients. 2019 , 119, 1162-1170		43

560	Etiological Research Using Observational Data, and Net Clinical Benefit. Simplicity and Practicality Matter. 2019 , 132, 671-672	
559	Atrial fibrillation and stroke: a practical guide. 2019 , 19, 208-224	13
558	Physician Estimation of Thrombotic and Bleeding Risks in Atrial Fibrillation: Let's Talk About Sex. 2019 , 35, 145-146	
557	Should anticoagulants be prescribed with Aspirin?. 2019 , 40, 212-213	
556	Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHADS-VASc and Support for CHADS-65. 2019 , 35, 547-549	
555	Impact of a Direct Oral Anticoagulant Population Management Tool on Anticoagulation Therapy Monitoring in Clinical Practice. 2019 , 53, 806-811	5
554	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. 2019 , 21, 1116-1125	8
553	Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. 2019 , 123, 1921-1926	4
552	Andexanet alfa for the reversal of factor Xa inhibitors. 2019 , 19, 387-397	5
551	Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban. 2019 , 35, 119-125	1
550	Antithrombotic Therapy and Regional Anesthesia. 2019 , 34, 439-446	1
549	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. 2019 , 133, 2269-2278	8
548	Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. 2019 , 48, 250-255	61
547	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. 2019 , 35, 619-633	35
546	Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?. 2019 , 176, 133-139	3
545	A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines. 2019 , 14, e0211695	4
544	Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review. 2019 , 24, 141-152	4
543	Recommendations on stroke prevention for patients having a CHADS-VASc score of 1 (males) or 2 (females) in 2019 atrial fibrillation guidelines. 2019 , 29, 427-428	5

542	Prevalence of Atrial Fibrillation in Hospital Encounters With End-Stage COPD on Home Oxygen: National Trends in the United States. <i>Chest</i> , 2019 , 155, 918-927	5.3	14
541	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. 2019 , 171, 181-189		44
540	Complex management of atrial fibrillation. 2019 , 2, 702-706		
539	EHRA White Paper: knowledge gaps in arrhythmia management-status 2019. 2019 , 21, 993-994		23
538	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. 2019 , 9, e033712		0
537	Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias. 2019 ,		78
536	Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. 2019 , 17, 206		4
535	Andexanet Alfa: Considerations and Practical Applications. 2019 , 18, 200-206		1
534	Should We Judge Stroke Risk by Static or Dynamic Risk Scores? A Focus on the Dynamic Nature of Stroke and Bleeding Risks in Patients With Atrial Fibrillation. 2019 , 74, 491-498		5
533	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. 2019 , 48, 236-243		4
532	Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. 2019 , 8,		16
531	Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center. 2019 , 25, 1076029619896619		17
530	Novel Echocardiographic Biomarkers in the Management of Atrial Fibrillation. 2019 , 12, 1		3
529	Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. 2019 , 74, 82-90		3
528	The Impact of Implementing an Advance Practice Pharmacist-Led Anticoagulation Clinic Within a Correctional Facility. 2021 , 34, 631-634		0
527	Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. 2019 , 17, 1709		6
526	Stroke prevention in atrial fibrillation: State of the art. 2019 , 287, 201-209		7
525	Oral anticoagulants and risk of dementia: A systematic review and meta-analysis of observational studies and randomized controlled trials. 2019 , 96, 1-9		30

524	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. 2019 , 132, 856-861	39
523	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. 2019 , 73, e13285	7
522	Feasibility and safety of a 12-week INR follow-up protocol over 2 years in an anticoagulation clinic: a single-arm prospective cohort study. 2019 , 47, 200-208	4
521	Risk stratification for stroke in atrial fibrillation: a critique. 2019 , 40, 1294-1302	20
520	Editorial commentary: Reversal agents in the era of non-vitamin k antagonists oral anticoagulants: Necessity or psychological crutch?. 2020 , 30, 91-92	
519	Understanding family involvement in body donation in Hong Kong: A qualitative study of registered donors and bereaved family members. 2020 , 28, 270-278	8
518	Antithrombotic prescriptions for many general surgery patients significantly increases the likelihood of post-operative bleeding complications. 2020 , 219, 453-459	1
517	Female sex and stroke in atrial fibrillation: an intriguing relationship. 2020 , 15, 175-179	2
516	Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation. 2020 , 25, 57-64	0
515	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. 2019 ,	59
514	Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. 2020 , 22, 162-169	14
513	Atrial Fibrillation in Heart Failure: Focus on Antithrombotic Management. 2020 , 16, 107-120	2
512	Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. 2020 , 109, 802-809	0
511	Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. 2020 , 49, 121-131	33
510	Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. 2020 , 40, 55-71	8
509	Key Points to Consider When Evaluating Andexxa for Formulary Addition. 2020 , 33, 20-24	8
508	Emergency Visits for Oral Anticoagulant Bleeding. 2020 , 35, 371-373	5
507	Impact of a pharmacist-led education and follow-up service on anticoagulation control and safety outcomes at a tertiary hospital in China: a randomised controlled trial. 2020 , 28, 97-106	3

506	Malignant hypertension: does this still exist?. 2020 , 34, 1-4	3
505	Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial. 2020 , 109, 1018-1024	2
504	Shunt thrombosis in pediatric patients undergoing staged cardiac reconstruction for cyanotic congenital heart disease. 2020 , 56, 101190	0
503	Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment. 2020 , 50, 330-336	1
502	Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. 2020 , 49, 316-320	5
501	Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. 2020 , 26, 100461	1
500	Impact of Anticoagulation on Mortality and Resource Utilization Among Critically Ill Patients With Major Bleeding. 2020 , 48, 515-524	6
499	Repeated mechanical thrombectomy for acute ischemic stroke in a dialysis patient: A case report and literature review. 2020 , 24, E13-E19	2
498	Atrial Fibrillation: Current Evidence and Management Strategies During the Perioperative Period. 2020 , 130, 2-13	7
497	Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. <i>Chest</i> , 2020 , 157, 1266-1277	5.3 18
496	Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes. 2020 , 22, 136-138	0
495	Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. 2020 , 58, 217-233	7
494	Does a dose relationship exist with prothrombin complex and factor Xa inhibitor reversal? An alternate perspective of Yohe et al. 2020 , 38, 686-687	
493	Patient Satisfaction With Extended International Normalized Ratio Follow-up Intervals in a Veteran Population. 2020 , 54, 442-449	
492	Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. 2020 , 49, 492-496	4
491	Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. 2020 , 40, 40-54	43
490	Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort. 2020 , 82, 105-111	39
489	Positioning for Perioperative Success: Insights from the European Society of Cardiology Statement on Atrial Fibrillation and Acute Heart Failure. 2020 , 34, 2871-2875	

488	Newer and Better? Comparing Direct Oral Anticoagulants to Warfarin in Patients With Traumatic Intracranial Hemorrhage. 2020 , 86, 1062-1066	1
487	A rare case report of apixaban-induced lichenoid eruption. 2020 , 11, 2042098620937884	2
486	Cardiac Electronic Devices: Future Directions and Challenges. 2020 , 13, 325-338	7
485	Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. 2020 , 196, 21-24	
484	ASSESSMENT OF TIME IN THERAPEUTIC RANGE WITH WARFARIN THERAPY IN PHARMACIST VERSUS USUAL CARE GROUP: A RETROSPECTIVE COHORT STUDY. 2020 , 68-71	
483	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. 2020 , 21, 1867-1881	2
482	Sex differences in atrial fibrillation. 2020 , 533-541	1
481	Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation: A Teachable Moment. 2020 , 180, 1246-1247	1
480	Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range?. 2020 , 4, 604-609	2
479	Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. 2021 , 35, 975-986	6
478	Letter by Ding et al Regarding Article, "Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation". 2020 , 51, e361-e362	
477	Endoscopy-Related Bleeding and Thromboembolic Events in Patients on Direct Oral Anticoagulants or Vitamin K Antagonists. 2020 ,	2
476	Real world utilization of Andexanet Alfa at a community hospital. 2021 , 45, 627-628	1
475	Atrial fibrillation: villain or bystander in vascular brain injury. 2020 , 22, M51-M59	8
474	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. 2020 , 18, 587-600	3
473	Facilitation of a multisite student topic discussion series using web-based conferencing technology. 2020 , 12, 843-849	1
472	Device-Detected Subclinical Atrial Fibrillation: The Anesthesiologist's Perspective. 2020 , 34, 2876-2880	
471	Direct oral anticoagulants in chronic kidney disease: an update. 2020 , 29, 489-496	0

470 Anticoagulation decisions in elderly patients with stroke. **2020**, 176, 692-700

469 Anticoagulant Therapy in Initially Low-Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors. **2020**, 9, e016271 4

468 Reply to "Key Points to Consider When Evaluating Andexxa for Formulary Addition". **2020**, 33, 323-326

467 Reply to "Non-vitamin K antagonist oral anticoagulants for atrial fibrillation in obese patients". **2020**, 130, 167-168

466 Proton Pump Inhibitor Utilization in Veteran Patients on Combined Antithrombotic Therapy and Validation of Simplified Bleeding Risk Score. **2020**, 40, 1219-1227 1

465 The cancer patient and cardiology. **2020**, 22, 2290-2309 22

464 Impact of Hospitalization and Medication Switching on Post-discharge Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation. **2020**, 40, 1022-1035 1

463 Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review. **2021**, 35, 1205-1215 3

462 Treatment implications of renal disease in patients with atrial fibrillation: The BALKAN-AF survey. **2020**, 36, 863-873 0

461 Cerebral venous thrombosis: a practical guide. **2020**, 20, 356-367 37

460 Predictors of oral anticoagulant-associated adverse events in seniors transitioning from hospital to home: a retrospective cohort study protocol. **2020**, 10, e036537 2

459 Low Body Weight Increases the Risk of Ischemic Stroke and Major Bleeding in Atrial Fibrillation: The COOL-AF Registry. **2020**, 9, 0

458 Attitudes toward anticoagulation for postoperative atrial fibrillation: A nationwide survey of VA providers. **2020**, 43, 1295-1301 4

457 Age-Dependent Anticoagulant Therapy for Atrial Fibrillation Patients with Intermediate Risk of Ischemic Stroke: A Nationwide Population-Based Study. **2021**, 121, 1151-1160 7

456 What do we do about atrial high rate episodes?. **2020**, 22, O42-O52 12

455 Updates on the use of direct oral anticoagulants for the management of chronic conditions. **2020**, 26, 44-58

454 Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. **2021**, 121, 1107-1114 3

453 Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. **2020**, 19, 178-186 0

452	Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study. 2020 , 18, 347	1
451	Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension-a Systematic Review. 2021 , 55, 995-1009	1
450	The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. 2020 , 19, 188	13
449	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. 2020 , 95, 2360-2369	3
448	Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. 2020 , 80, 35-44	5
447	The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation. 2020 , 9, 509-523	4
446	Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. 2020 , 77, 865-876	7
445	Monitoring of rivaroxaban levels in patients with class III obesity. 2020 , 77, 1013-1017	0
444	Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study. 2020 , 9,	5
443	Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Retrospective Cohort. 2020 , 17,	3
442	Ischemic Stroke in Patients With Sinus Node Disease, Atrial Fibrillation, and Other Cardiac Conditions. 2020 , 51, 1674-1681	4
441	Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population: The COOL-AF Registry. 2020 , 51, 1772-1780	10
440	Clinicians' views and experiences of prescribing oral anticoagulants for stroke prevention in atrial fibrillation: A qualitative meta-synthesis. 2020 , 15, e0232484	6
439	A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. 2020 , 192, 124-130	12
438	Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. 2020 , 3, e206424	14
437	Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. 2020 , 19, 63	17
436	Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. 2020 , 79, 31-36	6
435	Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. 2020 , 127, 176-183	8

434	Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. 2020 , 20, 301-309	13
433	Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. 2020 , 120, 894-898	14
432	A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus?. 2020 , 38, 1890-1903	6
431	Blood pressure targets in atrial fibrillation. 2020 , 41, 2860-2862	1
430	Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. 2020 , 4, 2366-2371	15
429	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.	25
428	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. 2020 , 36, 553-607	11
427	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. 2020 , 36, 553-607	7
426	Evaluation of the SAME-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. 2020 , 194, 178-182	1
425	Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: A nationwide cohort study. 2020 , 36, 668-677	13
424	The number needed to treat for net effect (NNTnet) as a metric for measuring combined benefits and harms. 2020 , 125, 100-107	10
423	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. 2020 , 80, 1065-1083	13
422	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. 2020 , 120, 1200-1207	23
421	Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. 2020 , 9, e017559	101
420	Performance of the microINR Point-of-Care System: A Multicenter Clinical Trial. 2020 , 120, 687-691	2
419	The Effect of Integrated Care Management on Dementia in Atrial Fibrillation. 2020 , 9,	12
418	Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. 2020 , 9,	12
417	Supporting anticoagulant treatment decision making to optimise stroke prevention in complex patients with atrial fibrillation: a cluster randomised trial. 2020 , 21, 102	2

416	Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. 2020 , 4, 562-568	4
415	Effectiveness of multimedia interventions in the provision of patient education on anticoagulation therapy: A review. 2020 , 103, 2009-2017	0
414	Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use. 2020 , 13, e005894	5
413	Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. 2020 , 50, e13221	0
412	Should We Adopt a Standard International Normalized Ratio Range of 2.0 to 3.0 for Asian Patients with Atrial Fibrillation? An Appeal for Evidence-Based Management, Not Eminence-Based Recommendations. 2020 , 120, 366-368	10
411	The Compelling Issue of Nonvitamin K Antagonist Oral Anticoagulant Adherence in Atrial Fibrillation Patients: A Systematic Need for New Strategies. 2020 , 120, 369-371	7
410	Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. 2020 , 4, 357-365	3
409	Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A population-based study. 2020 , 31, 1356-1363	2
408	Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation. 2020 , 19, 30	9
407	Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis. 2020 , 8,	2
406	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. 2020 , 9,	3
405	Should We Continue Assessing Glomerular Filtration Rate with the Cockcroft-Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem. 2020 , 9,	2
404	How I treat unexplained arterial thrombosis. 2020 , 136, 1487-1498	6
403	Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures. 2020 , 72, 1996-2005.e4	2
402	Vascular Disease Patient Information Page: Direct oral anticoagulants - 2020 update. 2020 , 25, 196-199	4
401	Successful Cerebral Hemorrhage Control with Prothrombin Complex Concentrate in a Patient on Edoxaban Therapy: A Case Report. 2020 , 11, 35-38	1
400	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer. 2020 , 120, 194-196	
399	Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. 2020 , 7, 54	9

398	The SAME-TTR score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia. 2020 , 50, 614-618	1
397	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. 2020 , 22, 496-505	13
396	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. 2020 , 9, 348-357	16
395	Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. 2020 , 26, 354-362	7
394	Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. 2020 , 75, 1523-1534	99
393	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. 2020 , 30, 387-388	0
392	Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation. 2020 , 18, 788-790	3
391	Dabigatran-induced esophagitis: A case report. 2020 , 99, e19890	2
390	Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions. 2020 , 8, e00593	0
389	A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation. 2020 , 42, 474-481	
388	Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation. 2021 , 34, 766-773	1
387	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. 2020 , 13, e008349	7
386	How I treat obese patients with oral anticoagulants. 2020 , 135, 904-911	10
385	Albumin and bleed risk in rivaroxaban treated patients. 2020 , 50, 1004-1011	2
384	Identification and early anticoagulation in patients with atrial fibrillation in the emergency department. 2021 , 44, 315-322	1
383	Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. 2021 , 7, 218-224	6
382	Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. 2021 , 21, 11-20	2
381	Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding. 2021 , 34, 112-120	12

380	Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. 2021 , 7, f3-f10		7
379	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. 2021 , 134, 67-75.e5		
378	Patterns and factors influencing oral anticoagulant prescription in people with atrial fibrillation and dementia: Results from UK primary care. 2021 , 87, 1056-1068		1
377	Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. 2021 , 289, 42-52		14
376	Oral Anticoagulants and Antiplatelet Agents in Patients With Atrial Fibrillation and Concomitant Critical Limb Ischemia: A Nationwide Cohort Study. 2021 , 37, 113-121		1
375	Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. 2021 , 53, 17-25		6
374	Optimization of atrial fibrillation care: management strategies and quality measures. 2021 , 7, 121-133		0
373	Effect of a novel pharmacist-led reporting system on appropriate use of direct-acting oral anticoagulants (DOACs) in a patient-centered medical home. 2021 , 51, 413-418		0
372	Turning Up to Eleven: Factor XI Inhibitors as Novel Agents to Maximize Safety and Maintain Efficacy in Thromboembolic Disease. 2021 , 46, 100696		2
371	Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry. <i>Chest</i> , 2021 , 159, 1507-1516	53	5
370	Drive-thru anticoagulation clinic: Can we supersize your care today?. 2021 , 61, e65-e67		2
369	Time to Deprescribe: A Time-Centric Model for Deprescribing at End of Life. 2021 , 24, 273-284		1
368	Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotype-Based Dosing Algorithms. 2021 , 41, 265-276		6
367	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. 2021 , 77, 629-656		45
366	Arrhythmias and Pregnancy: Management of Preexisting and New-Onset Maternal Arrhythmias. 2021 , 39, 67-75		0
365	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. 2021 , 23, 314-322		3
364	Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORP-AF General Long-Term Registry. 2021 , 75, e13701		1
363	Anticoagulant selection in relation to the SAME-TTR score in patients with atrial fibrillation: The GLORIA-AF registry. 2021 , 62, 152-157		1

362	Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. 2021 , 109, 1282-1292	6
361	Anticoagulation therapy in patients with traumatic brain injury: An Eastern Association for the Surgery of Trauma multicenter prospective study. 2021 , 169, 470-476	3
360	Stroke prevention strategies in high-risk patients with atrial fibrillation. 2021 , 18, 276-290	19
359	Trends in anticoagulation management services following incorporation of direct oral anticoagulants at a large academic medical center. 2021 , 51, 1050-1058	1
358	Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. 2021 , 323, 83-89	3
357	International Collaboration in Real-World Evidence Generation for Direct Acting Oral Anti-Coagulants. 2021 , 109, 299-301	1
356	Quality indicators for the care and outcomes of adults with atrial fibrillation. 2021 , 23, 494-495	23
355	Pathophysiology of atrial fibrillation and chronic kidney disease. 2021 , 117, 1046-1059	15
354	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. 2021 , 121, 140-149	8
353	Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?. 2021 , 47, 338-340	5
352	Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand. 2021 , 87, 1390-1400	0
351	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. 2021 , 7, 31-39	3
350	Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. 2021 , 7, 50-58	10
349	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. 2021 , 5, e84-e88	1
348	Anticoagulation and Antiplatelet Guidelines. 2021 , 201-223	
347	A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. 2021 , 46, 560-570	2
346	Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. 2021 , 7, 415-423	10
345	A novel prognostic tool to predict mortality in patients with atrial fibrillation: The BASIC-AF risk score. 2021 , 62, 339-348	5

344	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. 2021 , 7, f11-f19	10
343	Thromboembolism in Older Adults. 2020 , 7, 470016	1
342	Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines. 2021 , 66, 3698-3714	0
341	Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage. 2021 , 35, 255-261	15
340	Introducing the "Bleeding Team": Urgent Reconstruction of an Open Fracture in a Patient Receiving Acenocoumarol: A Case Report. 2021 , 11,	
339	Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?. 2021 , 22, 1061-1070	3
338	Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. 2021 , 27, 10760296211039020	1
337	Anticoagulant therapy in patients with atrial fibrillation after resection of the left atrial appendage. 2021 , 14, 190	
336	Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now?. 2021 , 51, 668-680	3
335	Impact of anemia on clinical outcomes of patients with atrial fibrillation: The COOL-AF registry. 2021 , 44, 415-423	2
334	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. 2021 , 10,	3
333	Editorial: Antithrombotic Prophylaxis in Patients With Atrial Fibrillation for Stroke Prevention: Evidence From Randomized Clinical Trials, Observational Studies, Methodological Modeling, and More. 2021 , 8, 658303	
332	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding. 2021 , 52, 511-520	5
331	Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. 2021 , 41, 379-393	0
330	Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region. 2021 , 77, 182-188	3
329	2020 Clinical Update in Liver Transplantation. 2021 ,	0
328	Clinical Factors Associated with Atrial Fibrillation Detection on Single-Time Point Screening Using a Hand-Held Single-Lead ECG Device. 2021 , 10,	11
327	Integrated care and outcomes in patients with atrial fibrillation and comorbidities. 2021 , 51, e13498	8

326	Exploring provider perspectives on patients with atrial fibrillation who are not prescribed anticoagulation therapy.	
325	Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. 2021 , 22, 163-169	2
324	Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis. 2021 , 23, 500-511	0
323	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. 2021 , 85, 80-85	6
322	Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. 2021 , 30, 1057-1069	1
321	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. 2021 , 42, 1698-1706	11
320	Atrial Fibrillation and Stroke. 2021 , 13, 243-255	0
319	Lower Risk of Dementia in Patients With Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Population-Based Cohort Study. 2021 , 10, e016437	3
318	Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. 2021 , 52, 1065-1068	12
317	Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). 2021 , 52, 863-871	3
316	Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. 2021 , 233, 109-121	9
315	Using a Patient Portal to Expand Warfarin Self-Management. 2021 , 17, 344-347	
314	Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand's COOL-AF registry. 2021 , 21, 117	0
313	Incident Strokes Among American Indian Individuals With Atrial Fibrillation. 2021 , 10, e019581	3
312	Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. 2021 , 1	6
311	Coagulopathy Management of an Acute Type A Aortic Dissection in a Patient Taking Apixaban. 2021 ,	0
310	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. 2021 , 165, 105418	7
309	How do you manage ANTICOagulant therapy in neurosurgery? The ANTICO survey of the Italian Society of Neurosurgery (SINCH). 2021 , 21, 98	2

308	Safety of reduced or absent antithrombotic therapy after left atrial appendage closure in patients affected by hereditary haemorrhagic telangiectasia and atrial fibrillation. 2021 ,	0
307	Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. 2021 , 10,	2
306	Optimizing indices of AF susceptibility and burden to evaluate AF severity, risk and outcomes. 2021 ,	16
305	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. 2021 , 86, 1-11	12
304	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease. 2021 , 57,	
303	Age-Related Clinical Outcomes of Patients with Non-Valvular Atrial Fibrillation: Insights from the COOL-AF Registry. 2021 , 16, 707-719	1
302	Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. 2021 , 16, e0249524	3
301	Frailty and cognitive impairment are not reasons to withhold anticoagulation in people with atrial fibrillation but screening could guide management. 2021 , 69, 1807-1810	
300	Clinical outcomes following rhythm control for atrial fibrillation: is early better?. 2021 , 19, 277-287	1
299	Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation. 2021 , 21, 573-580	0
298	Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. 2021 , 52, 1225-1233	7
297	Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. 2021 , 41, 365-387	0
296	Rationale and design of a prospective, multicenter, cross-sectional study of appropriateness evaluation of the prescription of non-vitamin K antagonist oral anticoagulants for Chinese atrial fibrillation patients (Chi-NOACs-AF trial). 2021 , 9, 580	0
295	Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control. 2021 , 30, 105620	
294	Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs. 2021 , 4, e219175	
293	Availability of Specific Direct Oral Anticoagulant Reversal Agents in US Hospitals. 2021 , 4, e2110079	1
292	Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage. 2021 , 41, 501-507	2
291	Review of Prothrombin Complex Concentrates Use in Apixaban and Rivaroxaban Associated Intracranial Hemorrhages. 2021 , 8971900211015059	

290	Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. 2021 ,	45
289	Physicians' Opinions on Anticoagulant Therapy in Patients with a Limited Life Expectancy. 2021 , 47, 735-744	2
288	Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. 2021 , 36, 793-812	4
287	Risk of Cardiovascular Complications in Patients with Persistent Atrial Fibrillation after Dissolution of a Thrombus in the Left Atrial Appendage. 2021 , 61, 17-22	1
286	Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis. 2021 , 12, 581293	8
285	Influence of gender on the clinical outcomes of Asian non-valvular atrial fibrillation patients: insights from the prospective multicentre COOL-AF registry. 2021 , 11, e043862	
284	Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation . 2021 , 23, 1502-1507	
283	Improving dynamic stroke risk prediction in non-anticoagulated patients with and without atrial fibrillation: Comparing common clinical risk scores and machine learning algorithms. 2021 ,	10
282	The Reply. 2021 , 134, e354-e355	
281	Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke. 2021 , 8, 665741	5
280	A case of acute pulmonary embolism with severe haemoptysis. 2021 ,	
279	Predictors of ischemic stroke for low-risk patients with atrial fibrillation: A matched case-control study. 2021 , 18, 702-708	3
278	Smoking Cessation after Diagnosis of New-Onset Atrial Fibrillation and the Risk of Stroke and Death. 2021 , 10,	3
277	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. 2021 , 10, 4405-4414	1
276	Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. 2021 , 1	6
275	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. 2021 , 236, 4-12	1
274	Review of the top 5 geriatrics studies of 2018-2019. 2021 , 154, 256-261	0
273	The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. 2021 , 31, 236-241	0

- 272 A retrospective study of antithrombotic therapy use in an outpatient haemodialysis unit. **2021**, 46, 1387-1394 0
- 271 Risk of Ischemic Stroke in Asymptomatic Atrial Fibrillation Incidentally Detected in Primary Care Compared with Other Clinical Presentations. **2021**, 7
- 270 How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation. **2021**, 22, 1807-1810 2
- 269 Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. **2021**, 1
- 268 Portal vein thrombosis: an overview of current treatment options. **2021**, 84, 327-332 2
- 267 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry. **2021**, 202, 24-30 1
- 266 Current practice and future prospects in left atrial appendage occlusion. **2021**, 44, 1236-1252 0
- 265 Atrial fibrillation in critically ill patients who received prolonged mechanical ventilation: a nationwide inpatient report. **2021**, 36, 1389-1401
- 264 Antithrombotic and Antiplatelet Drug Toxicity. **2021**, 37, 591-604 3
- 263 Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. **2021**, 37, 990-1006 4
- 262 Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. **2021**, 203, 121-130 2
- 261 The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation. **2021**, 10, 65-67 3
- 260 Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREncE in atrial fibrillation (SmartADHERE) a randomized clinical trial. **2021**, 237, 68-78 2
- 259 Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. **2021**, 174, 910-919 8
- 258 A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings. **2021**, 8971900211026839
- 257 Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. **2021**, 9, 3
- 256 Stroke Risk in Adults With Atrial Fibrillation According to Sex. **2021**, 30, 937-938
- 255 Patient-related factors associated with oral anticoagulation control: a population-based cohort study. **2021**, 29, 443-450

254	Optimal Management of Anticoagulation Therapy in Asian Patients With Atrial Fibrillation. 2021 , 85, 1245-1253	3
253	Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? a nationwide cohort study. 2021 ,	3
252	Paroxysmal atrial fibrillation is associated with early coagulation activity regardless of risk factors for embolism. 2021 , 69, 269-276	
251	Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer. 2021 , 89, 132-134	
250	Relationship between Chronic Kidney Disease, Time-in-Therapeutic Range, and Adverse Outcomes in Atrial Fibrillation: A post hoc Analysis from the AMADEUS Trial. 2021 , 1-7	
249	Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. 2021 , 10,	1
248	A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score. 2021 , 17, 685-692	
247	Atrial Fibrillation in Patients with Chronic Kidney Disease. 2021 , 39, 435-446	1
246	Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics. 2021 , 1	3
245	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. 2021 , 23, 1873-1891	2
244	Outcomes of patients with atrial fibrillation with and without diabetes: A propensity score matching of the COOL-AF registry. 2021 , 75, e14671	0
243	Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study. 2021 , 10,	0
242	A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease. 2021 , 1060028021, 1040093	
241	Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors. 2021 , 6, 918-925	0
240	A review of patient-led data acquisition for atrial fibrillation detection to prevent stroke. 2021 , 69, 102818	4
239	Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. 2021 , 10,	4
238	Comparison of HAS-BLED and ORBIT Bleeding Risk Scores in AF Patients treated with NOACs: A Report from the ESC-EHRA EORP-AF General Long-Term Registry. 2021 ,	5
237	AGA Technical Review on Coagulation in Cirrhosis. 2021 , 161, 1630-1656	2

236	Long-term antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease.	0
235	Management of cardiovascular complications of bruton tyrosine kinase inhibitors. 2021 ,	4
234	Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. 2021 , 19, 2984-2996	0
233	Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study. 2021 , 242, 123-131	1
232	Predicting atrial fibrillation after cryptogenic stroke via a clinical risk score-a prospective observational study. 2022 , 29, 149-157	1
231	Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights.. 2022 , 4, 56-64	0
230	Treatment Pattern of Antithrombotic Therapy over Time after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation in Real-World Practice in Korea. 2021 , 9,	
229	Atrial Fibrillation Diagnosis using ECG Records and Self-Report in the Community: Cross-Sectional Analysis from ELSA-Brasil. 2021 , 117, 426-434	0
228	Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation. 2021 , 26, 656-664	
227	AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. 2021 , 161, 1615-1627.e1	9
226	Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018. 2021 ,	0
225	Timing of Anticoagulation after Stroke in Patients with Non-Valvular Atrial Fibrillation Assessment of Provider Practices. 2021 , 30, 106014	
224	The Watchman device for preventing stroke in patients with atrial fibrillation. 2021 , 34, 33-38	
223	Stroke Prevention After Intracerebral Hemorrhage: Where Are We Now?. 2021 , 23, 162	1
222	Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home. 2021 , 206, 18-28	
221	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. 2021 , 51, 409-422	6
220	Long-term oral anticoagulant after catheter ablation for atrial fibrillation. 2021 , 23, 1157-1165	3
219	Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence. 2021 , 21, 419-433	7

218	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. 2020 , 133, 1195-1202.e2	44
217	Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. 2020 , 130, 106682	6
216	Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. 2020 , 22, O14-O27	5
215	Stroke prevention in atrial fibrillation: comparison of recent international guidelines. 2020 , 22, O53-O60	5
214	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. 2021 , 28, 611-621	7
213	Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry. 2019 , 25, 2649-2657	13
212	The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis. 2020 , 15, e0242922	9
211	Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. 2020 , 58, 1322-1331	6
210	Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. 2020 , 41, 1245-1251	2
209	Pharmacokinetics and Pharmacogenetics of Apixaban. 2020 , 16, 852-860	2
208	Current status of oral anticoagulant reversal strategies: a review. 2019 , 7, 411	18
207	From WOEST to AUGUSTUS: a review of safety and efficacy of triple versus dual antithrombotic regimens in patients with atrial fibrillation requiring percutaneous coronary intervention for acute coronary syndrome. 2019 , 7, 405	5
206	Antithrombotic Treatment after Atrial Fibrillation Ablation. 2020 , 26, 2703-2714	0
205	Management of atrial fibrillation: easy as ABC. 2019 , 110, 27-34	1
204	Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. 2020 , 18, 486-495	5
203	Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. 2020 , 10,	7
202	Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. 2019 , 49, 883-907	18
201	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. 2020 , 15, 1133-1180	82

200	Anticoagulation in Atrial Fibrillation Patients.	1
199	Physicians' and pharmacists' views and experiences regarding use of direct oral anticoagulants in clinical practice. 2021 ,	1
198	Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models. 2021 , 16, e0258192	0
197	Epidemiologí del ictus cardioembólico y su asociaci3n con la penetraci3n de los ACOD en Espa3a: primer estudio poblacional 2005-2018. 2021 ,	1
196	Stroke Prevention in Atrial Fibrillation. 2021 ,	1
195	Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias. 2021 , 10, CD013504	1
194	Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAME-TTR score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol. 2021 , 11, e051987	1
193	Feasibility and usability of a mobile health tool on anticoagulation management for patients with atrial fibrillation: a pilot study. 2021 , 1	1
192	AUDITS: Mnemonical Approach for Atrial Fibrillation With Coronary Artery Disease. 2021 ,	
191	Effectiveness of Direct Oral Anticoagulants in Obese Adults With Atrial Fibrillation: A Systematic Review of Systematic Reviews and Meta-Analysis. 2021 , 8, 732828	0
190	Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. 2021 ,	4
189	Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events. 2021 , 5, 100076	
188	Investigation of the effect of anticoagulant usage in the flow diverter stent treatment of the patient-specific cerebral aneurysm using the Lagrangian coherent structures. 2021 , 94, 86-93	
187	Atrial Fibrillation. 2017 ,	
186	Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation. 2018 , 9, 3446-3452	
185	Beneficios y riesgos de los anticoagulantes orales en la fibrilaci3n auricular. 2019 , 18, 9-14	
184	Review of the 2019 European Society of Cardiology Guidelines for the management of patients with supraventricular tachycardia: What is new, and what has changed?. 2019 , 22, 282-286	
183	VII. Strategy of Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 2019 , 108, 242-246	

- 182 Prise en charge hñostatique des hñorragies cñbrales sous anticoagulants oraux. **2019**, 28, 363-370
- 181 Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations. **2019**, 133-141 1
- 180 PROTOCOL FOR PRESCRIBING ANTICOAGULANTS FOR ATRIAL FLUTTER: ARE ALL ISSUES RESOLVED?. **2019**, 25, 309-315
- 179 Perspectives by a position statement on atrial fibrillation in acute heart failure a: Mechanisms and therapeutic approaches. **2020**, 23, 308-311
- 178 The Potential of Andexanet Alfa as a Reversal Agent for Direct Oral Anticoagulants. **2020**, 44-47
- 177 Use of SAME-TTRIScore to Predict the Quality of Anticoagulation Control in Patients with Atrial Fibrillation Receiving Warfarin in Thailand. **2020**, 103, 548-552 0
- 176 Mobile Health for Cardiovascular Disease: The New Frontier for AF Management: Observations from the Huawei Heart Study and mAFA-II Randomised Trial. **2020**, 9, 5-7 1
- 175 Efficacy and safety of direct oral anticoagulants and warfarin in atrial fibrillation patients as part of multicomponent antithrombotic therapy. **2020**, 46-56 1
- 174 Long-Term Medication Adherence Trajectories to Direct Oral Anticoagulants and Clinical Outcomes in Patients With Atrial Fibrillation. **2021**, 10, e021601 3
- 173 Meta-analysis comparing inappropriately low dose versus standard dose of direct oral anticoagulants in patients with atrial fibrillation. **2021**, 1
- 172 Cardiogastroenterology: Management of Elderly Cardiac Patients at Risk of GIB. 1
- 171 The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New?. **2020**, 16, 984-993
- 170 A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. **2021**, 5, 159-167 2
- 169 Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. **2021**, 20, 103-107 0
- 168 Dose Selection of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Non-Valvular Atrial Fibrillation. **2020**, 2, 1
- 167 Historical Evolution of the Anticoagulant-Antiplatelet Therapy in Patients with Mitral Valve Disease Associated to Atrial Fibrillation or Mechanical Valve Prosthesis. Role of Omeprazole. **2020**, 10, 698-706
- 166 Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation. **2020**, 11, 22-32 0
- 165 Pharmacists' warfarin therapy knowledge and counseling practices in the Eastern Province, Saudi Arabia: A cross-sectional study. **2020**, 12, 289-294

164	Evaluation of the effectiveness and safety of Direct Oral Anticoagulants in Elderly Patients with Non-Valvular Atrial Fibrillation who are not Candidates for Warfarin in real world setting. 2021,	
163	Residual Stroke Risk in Atrial Fibrillation. 2021, 10, 147-153	1
162	The Hospital-Community-Family-Based Telemedicine (HCFT-AF) Program for Integrative Management of Patients With Atrial Fibrillation: Pilot Feasibility Study. 2020, 8, e22137	1
161	Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. 2020, 77, 11-21	0
160	Early anticoagulant reversal after trauma: A Western Trauma Association critical decisions algorithm. 2021, 90, 331-336	3
159	Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition to Non-Vitamin-K Oral Anticoagulant (NOAC) Therapy. 2019, 44, 364	
158	Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition to Non-Vitamin-K Oral Anticoagulant (NOAC) Therapy. 2019, 44, 534	
157	Clinical Pharmacists Improve Patient Outcomes and Expand Access to Care. 2019, 36, 471-475	4
156	Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. 2019, 17, 1709	3
155	History of major bleeding predicts risk of clinical outcome of patients with atrial fibrillation: results from the COOL-AF registry. 2020, 17, 184-192	
154	Patients' satisfaction associated with portable coagulometers for warfarin monitoring: a cross-sectional study. 2020, 18, 386-395	
153	Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. 2020, 17, 612-620	
152	Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes.. 2022, 38, 67-76	
151	Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation. 2021, 2021, 9030005	
150	Comparison of the HAS-BLED versus ORBIT Scores in Predicting Major Bleeding Among Asians Receiving the Direct-Acting Oral Anticoagulants. 2021,	0
149	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. 2021, 37, 1389-1426	8
148	2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. 2021, 122,	16
147	Efficacy of RCHADS-VA score for predicting thromboembolism in Thai patients with non-valvular atrial fibrillation. 2021, 21, 540	0

146	A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation. 2021 , 16, e0259199	0
145	Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage. 2021 , 1	1
144	Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines.. 2022 , 39, 100-132	5
143	Electronic Health Record-Embedded Decision Support to Reduce Stroke Risk in Patients with Atrial Fibrillation - Study Protocol.. 2022 , 247, 42-42	
142	Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement.. 2022 , 327, 360-367	13
141	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation.. 2022 , 1	0
140	Successful percutaneous left atrial appendage occlusion for atrial fibrillation in a patient with mirror-image dextrocardia: a case report.. 2022 , 22, 20	0
139	Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants. 2022 , 23,	0
138	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.. 2021 , 12, 812018	1
137	Atrial Fibrillation. 2022 , 294-318	
136	Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer.. 2022 , 6, e12629	
135	Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation. 2022 ,	0
134	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.. 2022 ,	1
133	Chapter 14: Cardiac Arrhythmias. 2022 ,	
132	Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. 2022 , 2022, 1-8	
131	Growth differentiation factor 15 (GDF-15) in cardiovascular diseases: predicting bleeding after cardiac surgery and beyond that!. 2022 ,	0
130	Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report.. 2022 , 8971900221074938	0
129	Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. 239698732210769	0

128	Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.. 2022 , 24, A42-A55	0
127	Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention.. 2022 , 17, 14	0
126	Cardiovascular disease in hereditary haemophilia: The challenges of longevity.. 2022 ,	0
125	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry.. 2022 ,	1
124	Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.. 2022 , 17, e0264538	1
123	The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry.. 2022 , 2022, 5797257	
122	Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four Analyses of Randomized Clinical Trials.. 2022 , 9, 841341	
121	Validation of the CHA2DS2-VA Score (Excluding Female Sex) in Nonvalvular Atrial Fibrillation Patients: A Nationwide Population-Based Study.. 2022 , 11,	2
120	A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation.. 2022 , 13, 814724	1
119	Epidemiology of cerebral microbleeds and risk of adverse outcomes in atrial fibrillation: a systematic review and meta-analysis.. 2022 ,	
118	Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.. 2022 ,	0
117	Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.. 2022 , e023907	0
116	Relation of the 'Atrial Fibrillation Better Care (ABC) Pathway' to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists.. 2022 , 12,	0
115	Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?. 2022 , 9, 864899	
114	Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding.. 2022 , 3, e12655	0
113	Left Atrial Appendage Occlusion-A Choice or a Last Resort? How to Approach the Patient.. 2022 , 11, 135-142	
112	Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.. 2022 , 399, 1383-1390	9
111	Revised HAS-BLED score for bleeding prediction in atrial fibrillation patients with oral anticoagulants.	

110	AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.. 2022,	6
109	Atrial fibrillation.. 2022, 8, 21	5
108	Worldwide trends in antithrombotic therapy prescribing for atrial fibrillation: observations on the 'transition era' to non-vitamin K antagonist oral anticoagulants.. 2021,	
107	The effectiveness of split tablet dosing versus alternate-day dosing of warfarin: a randomized control trial.. 2021, 11, 24060	
106	Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program.. 2021,	1
105	Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight >120 kg. 2021, 208, 176-180	2
104	Chronic kidney disease and anticoagulation - Quick overview and practical guide. 2022, 9, 40	
103	[Cerebral venous thrombosis].. 2022, 122, 11-16	
102	The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.. 2022, 6, e12680	1
101	Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status.. 2022, 12, 6123	0
100	The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort.. 2022,	0
99	Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants.. 2022, 1	
98	Atrial Fibrillation in Heart Failure: Focus on Antithrombotic Management.. 2022, 40, 245-258	0
97	Optimization of DOAC management services in a centralized anticoagulation clinic.. 2022, 6, e12696	0
96	[Safety and effectiveness of oral anticoagulation in patients with atrial fibrillation and renal insufficiency - a real-world perspective].. 2022, 147, 617-624	
95	Predicting heart failure in atrial fibrillation patients: What about using biomarkers?. 2022, 251, 32-32	
94	SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated With Dabigatran Metabolism in a Healthy Chinese Population. 2022, 13,	1
93	Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants after Percutaneous Coronary Intervention. 2022, 453-464	

92	Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.. 2022 ,	2
91	NSAID Treatment Before and on the Early Onset of Acute Kidney Injury Had an Opposite Effect on the Outcome of Patients With AKI. 2022 , 13,	0
90	Haemostatic alterations and management of haemostasis in patients with cirrhosis.. 2022 , 76, 1291-1305	1
89	Preventing and Managing Falls in Adults With Cardiovascular Disease: A Scientific Statement From the American Heart Association.. 2022 , 101161HCQ000000000000108	2
88	Thromboembolism and bleeding in patients with atrial fibrillation and liver disease in a nationwide register-based cohort study. 2022 , 101952	1
87	Direct Oral Anticoagulants in Long-term Care Facilities: Rates of FDA-Approved Dosing. 2022 , 37, 215-220	
86	Features of the course and therapeutic aspects of deep vein thrombosis in elderly and senile patients. 2022 , 133	
85	DOACs in Mechanical and Bioprosthetic Heart Valves: A Narrative Review of Emerging Data and Future Directions. 2022 , 28, 107602962211035	1
84	Consensus document of the Sociedad Española de Patología Digestiva on massive nonvariceal gastrointestinal bleeding and direct-acting oral anticoagulants. 2022 ,	
83	Reversal of Selected Antithrombotics. 2022 , 215-220	
82	Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation for the Primary Care Setting in India: A Literature Review. 2022 ,	
81	Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis. 9,	
80	Putting the Novel Back in Oral Anticoagulants: Phase II Results of the Factor XIa Inhibitor Asundexian. 2022 , 19,	
79	Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. 2022 , 19, e1004003	1
78	Social Determinants of Health, Income, and Anticoagulation Outcomes. 2022 , 79, 2514-2515	0
77	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry.	1
76	Oral anticoagulant adherence and switching in patients with atrial fibrillation: A prospective observational study. 2022 ,	0
75	Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges. jnnp-2020-325249	

74	Impact of Medication Adherence on the Association Between Oral Anticoagulant Use and Risk of Dementia: A Retrospective Cohort Study using the Japanese Claims Database.	0
73	Atrial Fibrillation and Stroke.	
72	Exploring clinician perspectives on patients with atrial fibrillation who are not prescribed anticoagulation therapy. 2022 , 100062	
71	Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations. 2022 , 5, e2222089	1
70	New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies.	2
69	Effectiveness and Safety of Antithrombotic Medication in Patients With Atrial Fibrillation and Intracranial Hemorrhage: Systematic Review and Meta-Analysis.	
68	A nomogram to predict left atrial appendage thrombus and spontaneous echo contrast in non-valvular atrial fibrillation patients. 2022 , 22,	0
67	Impact of pharmacist intervention on anticoagulation management and risk for potential COVID-19 exposure during the COVID-19 pandemic. 2022 ,	
66	What Drugs Decrease Perioperative Bleeding?. 2023 , 506-518	
65	Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism. 2022 ,	
64	Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry.	0
63	Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation.	1
62	Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper.	3
61	Dosing Medications for Coagulopathy Reversal in Patients with Extreme Obesity. 2022 ,	
60	Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program. 2022 , 159, 177-182	
59	A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIA registry. 1-9	0
58	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).	4
57	Stroke Prevention in Atrial Fibrillation. 2022 , 2, 395-411	

- 56 Four-factor prothrombin complex concentrate administration after expanding intracranial hemorrhage status post administration of andexanet alfa. **2022,**
- 55 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). 39
- 54 Stroke Prevention in Atrial Fibrillation. **2022,**
- 53 Whether it is safe to start anticoagulation after intracranial hemorrhage within 2 weeks: A systematic review and meta-analysis.
- 52 Successful use of therapeutic anticoagulation therapy in two patients with moderate stroke from the second day of onset: A case report and literature review. **2022,** 82, 104726 ○
- 51 Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA2DS2-VASc Score 0: A Korean Multi-Center Cohort. **2022,** 63, 892 ○
- 50 Use of Direct Oral Anticoagulant and Associated Bleeding and Thrombotic Complication after Lower Extremity Bypass. Publish Ahead of Print, ○
- 49 Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants. **2022,** 5, e2229333 ○
- 48 Outcomes with direct acting oral anticoagulants in patients with a history of bariatric surgery: a retrospective cohort study. **2022,** ○
- 47 Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization. 9, ○
- 46 Improving risk prediction for death, stroke, and bleeding in Asian patients with atrial fibrillation. ○
- 45 Safety of Nonvitamin K Antagonists Compared with Warfarin in Patients with Atrial Fibrillation and End-Stage Kidney Disease. **2022,** 115, 794-798 ○
- 44 Development and validation of a bleeding risk prediction score for patients with mitral valve stenosis and atrial fibrillation or mechanical heart valves receiving long-term warfarin therapy. ○
- 43 Personalized approach using wearable technology for early detection of atrial fibrillation in high-risk primary care patients (PATCH-AF): Study protocol for a cluster randomized controlled trial. **2022,** 254, 172-182 ○
- 42 Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system. 9, ○
- 41 Impact of Concomitant Fluconazole on Direct Oral Anticoagulant Bleeding Risk. ○
- 40 Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper ○
- 39 Preprocedural Multimodality Imaging in Atrial Fibrillation. **2022,** 15, ○

- 38 Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry. ○
- 37 Changing trends and factors influencing anticoagulant use in patients with acute ischemic stroke and NVAf at discharge in the NOACs era. **2023**, 32, 106905 ○
- 36 Efficacy and Safety Assessment of Rivaroxaban for the Treatment of Cerebral Venous Sinus Thrombosis in a Chinese Population. **2022**, 28, 107602962211440 ○
- 35 Prescribing Patterns of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Retrospective Cohort Analysis. **2022**, 27, 107424842211422 ○
- 34 Direct Oral Anticoagulants. An Updated Systematic Review of its Clinical Pharmacology and Clinical Effectiveness and Safety in Patients with Nonvalvular Atrial Fibrillation. ○
- 33 An Evaluation of Time to Therapeutic Range of Intravenous Unfractionated Heparin After Transitioning From Direct Oral Factor Xa Inhibitors. 001857872211337 ○
- 32 Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation. **2022**, 10, ○
- 31 Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation. **2022**, 17, e0277744 ○
- 30 Utilization of Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. ○
- 29 Imaging in atrial fibrillation: a way to assess atrial fibrosis and remodeling to assist decision-making. **2022**, ○
- 28 Atrial fibrillation and stroke. 1
- 27 Hemostatic Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in Doac-Associated Intracranial Hemorrhage. 089719002211480 ○
- 26 Antiplatelet Agents and Oral Anticoagulant Use in Patients with Atrial Fibrillation and Carotid Artery Disease After First-Time Ischaemic Stroke. ○
- 25 Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAME-TT2R2 score. **2023**, 23, ○
- 24 Periprocedural Anticoagulation. ○
- 23 Left Atrial Appendage Occlusion—A Choice or a Last Resort? How to Approach the Patient. **2023**, 15, 133-140 ○
- 22 Impact of Achieving Blood Pressure Targets and High Time in Therapeutic Range on Clinical Outcomes in Patients With Atrial Fibrillation Adherent to the Atrial Fibrillation Better Care Pathway: A Report From the COOL-AF Registry. **2023**, 12, ○
- 21 Plaque Progression Differences Between Apixaban and Rivaroxaban in Patients With Atrial Fibrillation Measured With Cardiac Computed Tomography and Plaque Quantification. Publish Ahead of Print, ○

- 20 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country. **2023**, 23, 173-183 ○
- 19 Predicting Heart Failure in Patients with Atrial Fibrillation: A Report from the Prospective COOL-AF Registry. **2023**, 12, 1265 ○
- 18 Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency. **2023**, 9, 109-118 ○
- 17 Precautions during Direct Oral Anticoagulant Introduction in Gynecologic Malignancies: A Single-Center Retrospective Cohort Study. **2023**, 15, 1132 ○
- 16 Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. **2023**, 147, 782-794 1
- 15 Outcome of novel oral anticoagulant versus warfarin in frail elderly patients with atrial fibrillation: a systematic review and meta-analysis of retrospective studies. 1-11 ○
- 14 Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. **2023**, 79, 541-551 ○
- 13 Causes of death of patients with non-valvular atrial fibrillation in Asians. **2023**, 18, e0282455 ○
- 12 The Value of Anticoagulation Management Combining Telemedicine and Self-Testing in Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Volume 19, 279-290 ○
- 11 A quality-improvement initiative to convert patients from warfarin to non-vitamin K antagonist oral anticoagulants. Publish Ahead of Print, ○
- 10 Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?. **2023**, 13, 1160 ○
- 9 Predicting the Absolute Risk of Ischemic Stroke in Asian Patients with Atrial Fibrillation: Comparing the COOL-AF Risk Score with CARS/mCARS Models for Absolute Risk and the CHA2DS2-VASc Score. **2023**, 12, 2449 ○
- 8 Trends in antiplatelet strategies 12-months following coronary stent placement in anticoagulated patients. **2023**, 23, ○
- 7 Efficacy and safety of early anticoagulation after endovascular treatment in patients with atrial fibrillation. svn-2022-002082 ○
- 6 Visual acuity time in range: a novel concept to describe consistency in treatment response in diabetic macular oedema. ○
- 5 Prevention of falls in the elderly and senile patients with cardiovascular diseases. **2023**, 14-28 ○
- 4 Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study. **2023**, 18, e0284425 ○
- 3 Three-year outcomes of patients with non-valvular atrial fibrillation: the COOL-AF registry. **2023**, 20, 163-173 ○

- 2 OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants. **2023**, 227, 17-24 ○
- 1 Predictors of participation in atrial fibrillation screening among community residents in China. **2023**, 61, 59-64 ○